A novel CPT1A covalent inhibitor modulates fatty acid oxidation and CPT1A-VDAC1 axis with therapeutic potential for colorectal cancer

• DOI: 10.1016/j.redox.2023.102959
• Publication Date: 2023-11-10T07:33:23Z
• Authors: Anni Hu; Hang Wang; Qianqian Xu; Yuqi Pan; Zeyu Jiang; Sheng Li; Yi Qu; Yili Hu; Hao Wu; Xinzhi Wang
• Keywords: Medicine (General); Carnitine O-Palmitoyltransferase; QH301-705.5; Fatty Acids; Apoptosis; Lipid Metabolism; Colorectal cancer; CPT1A; 3. Good health; 2,6-Dihydroxypeperomin B; VDAC1; R5-920; Animals; Voltage-Dependent Anion Channels; Biology (General); Colorectal Neoplasms; Covalent inhibitor; Oxidation-Reduction; Research Paper

Colorectal cancer (CRC) is a common and deadly disease of the digestive system, but its targeted therapy is hampered by the lack of reliable and specific biomarkers. Hence, discovering new therapeutic targets and agents for CRC is an urgent and challenging task. Here we report that carnitine palmitoyltransferase 1A (CPT1A), a mitochondrial enzyme that catalyzes fatty acid oxidation (FAO), is a potential target for CRC treatment. We show that CPT1A is overexpressed in CRC cells and that its inhibition by a secolignan-type compound, 2,6-dihydroxypeperomin B (DHP-B), isolated from the plant Peperomia dindygulensis, suppresses tumor cell growth and induces apoptosis. We demonstrate that DHP-B covalently binds to Cys96 of CPT1A, blocks FAO, and disrupts the mitochondrial CPT1A-VDAC1 interaction, leading to increased mitochondrial permeability and reduced oxygen consumption and energy metabolism in CRC cells. We also reveal that CPT1A expression correlates with the survival of tumor-bearing animals and that DHP-B exhibits anti-CRC activity in vitro and in vivo. Our study uncovers the molecular mechanism of DHP-B as a novel CPT1A inhibitor and provides a rationale for its preclinical development as well as a new strategy for CRC targeted therapy.